Skip to content
HowShorted

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2022

In 2022, ARROWHEAD PHARMACEUTICALS, INC.'s disclosed short interest ran from 2.67% of shares outstanding on 14 Jan 2022 to 4.47% on 30 Dec 2022, a change of +1.80 percentage points. The year's high was 5.02% on 30 Jun 2022 and its low 2.67% on 14 Jan 2022, averaging 3.86% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.36 days on 29 Jul 2022. Full history: ARROWHEAD PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ARROWHEAD PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
2.67% (14 Jan 2022)
End of year
4.47% (30 Dec 2022)
Change
+1.80 pp
High
5.02% (30 Jun 2022)
Low
2.67% (14 Jan 2022)
Average
3.86%
Highest days to cover
7.36 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20222.67%4.26
31 Jan 20222.73%3.69
15 Feb 20222.94%4.4310-Q filed, results (8-K)
28 Feb 20223.19%4.10
15 Mar 20223.65%6.74
31 Mar 20223.74%4.79
14 Apr 20223.48%5.45
29 Apr 20223.79%6.49
13 May 20224.49%4.1210-Q filed, results (8-K)
31 May 20224.23%5.23
15 Jun 20224.71%6.57
30 Jun 20225.02%4.70
15 Jul 20224.66%6.29
29 Jul 20224.56%7.36
15 Aug 20224.13%5.6310-Q filed, results (8-K)
31 Aug 20223.95%6.17
15 Sep 20224.02%5.48
30 Sep 20223.65%4.10
14 Oct 20223.72%5.52
31 Oct 20223.68%5.44
15 Nov 20223.52%3.50
30 Nov 20223.74%4.2710-K filed, results (8-K)
15 Dec 20224.01%5.75
30 Dec 20224.47%4.35

See also: ARROWHEAD PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.